Skip to main content
SpringerLink
Log in

Role of Anti-thymocyte Globulin in Stem Cell Transplant

  • Chapter
  • First Online:
Basics of Hematopoietic Stem Cell Transplant

  • 421 Accesses

Abstract

Anti-thymocyte globulin (ATG) has been used as an immunosuppressive agent in conditioning regimens for stem cell transplant (SCT). ATG directly binds to and kills T and B cells, and also effects thymic epithelial cells, impairing thymopoiesis. ATG has been increasingly used in allogeneic SCT for prevention of graft rejection and graft-versus-host disease. Horse ATG is more efficacious than rabbit ATG for treating aplastic anemia, however, for GVHD prophylaxis, rabbit ATG is more efficacious than horse ATG. The drawback of ATG is that its use is associated with increased risk of disease relapse and infections. A better understanding of ATG use is needed to harness the beneficial effects and avoid the deleterious effects of ATG in allo SCT.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21(7):1387–94.

    Article  CAS  PubMed  Google Scholar 

  2. Fang L, Fehse B, Engel M, Zander A, Kröger N. Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells. Transplantation. 2005;79(3):369–71.

    Article  CAS  PubMed  Google Scholar 

  3. Grüllich C, Ziegler C, Finke J. Rabbit anti T-lymphocyte globulin induces apoptosis in peripheral blood mononuclear cell compartments and leukemia cells, while hematopoetic stem cells are apoptosis resistant. Biol Blood Marrow Transplant. 2009;15(2):173–82.

    Article  PubMed  Google Scholar 

  4. Liu H, Qin Y, Wang X, Xie K, Yang Y, Zhu J, et al. Polyclonal rabbit antithymocyte globulin induces apoptosis and has cytotoxic effects on human leukemic cells. Clin Lymphoma Myeloma Leuk. 2012;12(5):345–54.

    Article  CAS  PubMed  Google Scholar 

  5. Yoshimi A, Ito M, Kojima S. Leukemic cell death induced by antithymocyte globulin. Leuk Res. 2005;29(7):821–7.

    Article  CAS  PubMed  Google Scholar 

  6. Storek J, Mohty M, Boelens JJ. Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(6):959–70.

    Article  CAS  PubMed  Google Scholar 

  7. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365(5):430–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Hagen P, Wagner JE, DeFor TE, Dolan M, Arora M, Warlick E, et al. The effect of equine antithymocyte globulin on the outcomes of reduced intensity conditioning for AML. Bone Marrow Transplant. 2014;49(12):1498–504.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Bosch M, Dhadda M, Hoegh-Petersen M, Liu Y, Hagel LM, Podgorny P, et al. Immune reconstitution after antithymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy. 2012;14(10):1258–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Feng X, Scheinberg P, Biancotto A, Rios O, Donaldson S, Wu C, et al. In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia. Haematologica. 2014;99(9):1433–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. McCune JS, Bemer MJ, Long-Boyle J. Pharmacokinetics, pharmacodynamics, and pharmacogenomics of immunosuppressants in allogeneic hematopoietic cell transplantation: Part II. Clin Pharmacokinet. 2016;55(5):551–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol. 2006;17(10):2844–53.

    Article  CAS  PubMed  Google Scholar 

  13. Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124(3):344–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Haidinger M, Geyeregger R, Poglitsch M, Weichhart T, Zeyda M, Vodenik B, et al. Antithymocyte globulin impairs T-cell/antigen-presenting cell interaction: disruption of immunological synapse and conjugate formation. Transplantation. 2007;84(1):117–21.

    Article  CAS  PubMed  Google Scholar 

  15. Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374(1):43–53.

    Article  PubMed  Google Scholar 

  16. Faulkner L, Uderzo C, Khalid S, Marwah P, Soni R, Yaqub N, et al. ATG vs thiotepa with busulfan and cyclophosphamide in matched-related bone marrow transplantation for thalassemia. Blood Adv. 2017;1(13):792–801.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Bacigalupo A. ATG in allogeneic stem cell transplantation: standard of care in 2017? Point. Blood Adv. 2017;1(9):569–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006;12(5):560–5.

    Article  PubMed  Google Scholar 

  19. Portier D, Sabo R, Roberts C, Fletcher D, Meier J, Clark W, et al. Anti-thymocyte globulin for conditioning in matched unrelated donor hematopoietic cell transplantation provides comparable outcomes to matched related donor recipients. Bone Marrow Transplant. 2012;47(12):1513–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2020;7(2):e100–11.

    Article  PubMed  Google Scholar 

  21. Bailén R, Kwon M, Pascual-Cascón MJ, Ferrà C, Sanz J, Gallardo-Morillo A, et al. Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation. Ann Hematol. 2021;100(2):541–53.

    Article  PubMed  Google Scholar 

  22. Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant. 2014;49(2):168–73.

    Article  CAS  PubMed  Google Scholar 

  23. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855–64.

    Article  CAS  PubMed  Google Scholar 

  24. Socié G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood. 2011;117(23):6375–82.

    Article  PubMed  Google Scholar 

  25. Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016;17(2):164–73.

    Article  CAS  PubMed  Google Scholar 

  26. Veys P, Wynn RF, Ahn KW, Samarasinghe S, He W, Bonney D, et al. Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia. Blood. 2012;119(25):6155–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Deeg HJ, Storer BE, Boeckh M, Martin PJ, McCune JS, Myerson D, et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant. 2006;12(5):573–84.

    Article  CAS  PubMed  Google Scholar 

  28. Soiffer RJ, LeRademacher J, Ho V, Kan F, Artz A, Champlin RE, et al. Impact of immune modulation with anti–T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011;117(25):6963–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Devillier R, Labopin M, Chevallier P, Ledoux MP, Socié G, Huynh A, et al. Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. Bone Marrow Transplant. 2018;53(4):431–7.

    Article  CAS  PubMed  Google Scholar 

  30. Langston AA, Prichard JM, Muppidi S, Nooka A, Lechowicz MJ, Lonial S, et al. Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors. Bone Marrow Transplant. 2014;49(2):185–9.

    Article  CAS  PubMed  Google Scholar 

  31. Baron F, Labopin M, Blaise D, Lopez-Corral L, Vigouroux S, Craddock C, et al. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49(3):389–96.

    Article  CAS  PubMed  Google Scholar 

  32. Baron F, Mohty M, Blaise D, Socié G, Labopin M, Esteve J, et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102(2):224–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Blaise D, Tabrizi R, Boher JM, Le Corroller-Soriano AG, Bay JO, Fegueux N, et al. Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation. Cancer. 2013;119(3):602–11.

    Article  CAS  PubMed  Google Scholar 

  34. Blaise D, Castagna L. Do different conditioning regimens really make a difference? Hematol Am Soc Hematol Educ Program. 2012;2012:237–45.

    Article  Google Scholar 

  35. Appelbaum FR, Bacigalupo A, Soiffer R. Anti-T cell antibodies as part of the preparative regimen in hematopoietic cell transplantation—a debate. Biol Blood Marrow Transplant. 2012;18(1 Suppl):S111–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Kumar A, Reljic T, Hamadani M, Mohty M, Kharfan-Dabaja MA. Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. Bone Marrow Transplant. 2019;54(7):1094–106.

    Article  CAS  PubMed  Google Scholar 

  37. Bonifazi F, Rubio MT, Bacigalupo A, Boelens JJ, Finke J, Greinix H, et al. Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. Bone Marrow Transplant. 2020;55(6):1093–102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Na IK, Wittenbecher F, Dziubianau M, Herholz A, Mensen A, Kunkel D, et al. Rabbit antithymocyte globulin (thymoglobulin) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients. Haematologica. 2013;98(1):23–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Sharma SK. What a clinical hematologist should know about T cells? Int Blood Res Rev. 2020:20–32.

    Google Scholar 

  40. Zand MS, Vo T, Huggins J, Felgar R, Liesveld J, Pellegrin T, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation. 2005;79(11):1507–15.

    Article  CAS  PubMed  Google Scholar 

  41. Gandhi S, Kulasekararaj AG, Mufti GJ, Marsh JCW. Allogeneic stem cell transplantation using alemtuzumab-containing regimens in severe aplastic anemia. Int J Hematol. 2013;97(5):573–80.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hemato-oncology and Bone Marrow Transplantation, Venkateshwar Hospital, New Delhi, Delhi, India

    Sanjeev Kumar Sharma

Authors
  1. Sanjeev Kumar Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sharma, S.K. (2023). Role of Anti-thymocyte Globulin in Stem Cell Transplant. In: Basics of Hematopoietic Stem Cell Transplant. Springer, Singapore. https://doi.org/10.1007/978-981-19-5802-1_18

Download citation

  • DOI: https://doi.org/10.1007/978-981-19-5802-1_18

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-19-5801-4

  • Online ISBN: 978-981-19-5802-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation